Jun. 23 at 12:12 PM
H.C. Wainwright reiterated
$ORKA Buy-
$120
UCBJY JNJ - PTGX ALMS TAK
H.C. Wainwright commented on y'day's
$APGE and
$ABBV M&A deal, pointing to Apogee's similarity to Oruka, as it was incepted by privately-held Paragon Therapeutics, and additionally said: In our view, Oruka and Apogee have many points of commonality, including a focus on I&I (particularly inflammatory skin diseases) and the intent to advance investigational agents with best-in-disease potential. We reiterate our Buy rating and 12-month price target of
$120 per share.